Submitted:
23 May 2025
Posted:
26 May 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Setting
2.2. Study Population and Inclusion Criteria
2.3. Sample Collection and Treatment
2.4. RP−HPLC-ESI-MS Analysis
2.5. Intact Protein/Peptide Characterization and Relative Quantification
2.6. Statistical Analysis
3. Results
4. Discussion
5.Conclusions
Author Contributions
Acknowledgments
Conflicts of Interest
References
- Ozsurekci, Y.; Aykac, K. Oxidative Stress Related Diseases in Newborns. Oxid Med Cell Longev. 2016, 2016, 2768365. [Google Scholar] [CrossRef] [PubMed]
- Poljšak, B.; Fink, R. The protective role of antioxidants in the defence against ROS/RNS-mediated environmental pollution. Oxid Med Cell Longev. 2014, 2014, 671539. [Google Scholar] [CrossRef]
- Jomova, K.; Raptova, R.; Alomar, S.Y.; Alwasel, S.H.; Nepovimova, E.; Kuca, K.; Valko, M. Reactive oxygen species, toxicity, oxidative stress, and antioxidants: Chronic diseases and aging. Arch Toxicol. 2023, 97, 2499–2574. [Google Scholar] [PubMed]
- Torres-Cuevas, I.; Parra-Llorca, A.; Sánchez-Illana, A.; Nuñez-Ramiro, A.; Kuligowski, J.; Cháfer-Pericás, C.; Cernada, M.; Escobar, J.; Vento, M. Oxygen and oxidative stress in the perinatal period. Redox biology 2017, 12, 674–681. [Google Scholar] [CrossRef] [PubMed]
- Moore, T.A.; Ahmad, I.M.; Zimmerman, M.C. Oxidative Stress and Preterm Birth: An Integrative Review. Biological research for nursing 2018, 20, 497–512. [Google Scholar] [CrossRef]
- Perez, M.; Robbins, M.E.; Revhaug, C.; Saugstad, O.D. Oxygen radical disease in the newborn, revisited: Oxidative stress and disease in the newborn period. Free radical biology & medicine 2019, 142, 61–72. [Google Scholar]
- Cannavò, L.; Perrone, S.; Viola, V.; Marseglia, L.; Di Rosa, G.; Gitto, E. Oxidative Stress and Respiratory Diseases in Preterm Newborns. International journal of molecular sciences 2021, 22, 12504. [Google Scholar] [CrossRef]
- Peña-Bautista, C.; Durand, T.; Vigor, C.; Oger, C.; Galano, J.M.; Cháfer-Pericás, C. Non-invasive assessment of oxidative stress in preterm infants. Free radical biology & medicine 2019, 142, 73–81. [Google Scholar]
- De Almeida, V.O.; Pereira, R.A.; Amantéa, S.L.; Rhoden, C.R.; Colvero, M.O. Neonatal diseases and oxidative stress in premature infants: An integrative review. Jornal de pediatria 2022, 98, 455–462. [Google Scholar] [CrossRef]
- Gerstner, B.; DeSilva, T.M.; Genz, K.; Armstrong, A.; Brehmer, F.; Neve, R.L.; Felderhoff-Mueser, U.; Volpe, J.J.; Rosenberg, P.A. Hyperoxia causes maturation-dependent cell death in the developing white matter. J Neurosci. 2008, 28, 1236–1245. [Google Scholar] [CrossRef]
- Volpe, J. Neurobiology of Periventricular Leukomalacia in the Premature Infant. Pediatr Res. 2001, 50, 553–562. [Google Scholar] [CrossRef] [PubMed]
- Marseglia, L.; D’Angelo, G.; Manti, S.; Aversa, S.; Reiter, R.J.; Antonuccio, P.; Centorrino, A.; Romeo, C.; Impellizzeri, P.; Gitto, E. Oxidative stress mediated damage in newborns with necrotizing enterocolitis: A possible role of melatonin. American Journal of Perinatology 2015, 32, 905–909. [Google Scholar] [PubMed]
- Perrone, S.; Tataranno, M.L.; Santacroce, A.; Negro, S.; Buonocore, G. The role of oxidative stress on necrotizing enterocolitis in very low birth weight infants. Current Pediatric Reviews 2014, 10, 202–207. [Google Scholar] [CrossRef]
- Fevereiro-Martins, M.; Marques-Neves, C.; Guimarães, H.; Bicho, M. Retinopathy of prematurity: A review of pathophysiology and signaling pathways. Survey of ophthalmology 2023, 68, 175–210. [Google Scholar] [CrossRef] [PubMed]
- Graziosi, A.; Perrotta, M.; Russo, D.; Gasparroni, G.; D'Egidio, C.; Marinelli, B.; Di Marzio, G.; Falconio, G.; Mastropasqua, L.; Li Volti, G.; et al. Oxidative Stress Markers and the Retinopathy of Prematurity. Journal of clinical medicine 2020, 9, 2711. [Google Scholar] [CrossRef]
- Kimble, A.; Robbins, M.E.; Perez, M. Pathogenesis of Bronchopulmonary Dysplasia: Role of Oxidative Stress from 'Omics' Studies. Antioxidants 2022, 11, 2380. [Google Scholar] [CrossRef]
- Wang, J.; Dong, W. Oxidative stress and bronchopulmonary dysplasia. Gene 2018, 678, 177–183. [Google Scholar] [CrossRef]
- Ferrante, G.; Montante, C.; Notarbartolo, V.; Giuffrè, M. Antioxidants: Role the in prevention and treatment of bronchopulmonary dysplasia. Paediatric respiratory reviews 2022, 42, 53–58. [Google Scholar] [CrossRef]
- Capasso, L.; Vento, G.; Loddo, C.; Tirone, C.; Iavarone, F.; Raimondi, F.; Dani, C.; Fanos, V. Oxidative Stress and Bronchopulmonary Dysplasia: Evidences From Microbiomics, Metabolomics, and Proteomics. Front Pediatr. 2019, 13, 30. [Google Scholar] [CrossRef]
- Tirone, C.; Iavarone, F.; Tana, M.; Lio, A.; Aurilia, C.; Costa, S.; Castagnola, M.; Messana, I.; Vento, G. Oxidative and Proteolytic Inactivation of Alpha-1 Antitrypsin in Bronchopulmonary Dysplasia Pathogenesis: A Top-Down Proteomic Bronchoalveolar Lavage Fluid Analysis. Frontiers in pediatrics 2021, 9, 597415. [Google Scholar] [CrossRef]
- Gitto, E.; Pellegrino, S.; Gitto, P.; Barberi, I.; Reiter, R.J. Oxidative stress of the newborn in the pre- and postnatal period and the clinical utility of melatonin. J Pineal Res. 2009, 46, 128–139. [Google Scholar] [CrossRef] [PubMed]
- Varsila, E.; Pesonen, E.; Andersson, S. Early protein oxidation in the neonatal lung is related to development of chronic lung disease. Acta paediatr. 1995, 84, 1296–1299. [Google Scholar] [CrossRef] [PubMed]
- Vento, G.; Mele, M.C.; Mordente, A.; Romagnoli, C.; Matassa, P.G.; Zecca, E.; Zappacosta, B.; Persichilli, S. High total antioxidant activity and uric acid in tracheobronchial aspirate fluid of preterm infants during oxidative stress: An adaptive response to hyperoxia? Acta Paediatr. 2000, 89, 336–342. [Google Scholar] [CrossRef] [PubMed]
- Ogihara, T.; Hirnao, K.; Morinobu, T.; Kim, H.-S.; Hiroi, M.; Ogihara, H.; Tami, H. Raised concentrations of aldehyde lipid peroxidation products in premature infants with chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 1999, 80, F21–F25. [Google Scholar] [CrossRef]
- Inder, T.E.; Graham, P.; Sanderson, K.; Taylor, B.J. Lipid peroxidation as a measure of oxygen free radical damage in the very low birthweight infant. Arch Dis Child Fetal Neonatal Ed. 1994, 70, F107–F111. [Google Scholar] [CrossRef]
- Gladstone, I.M.; Levine, R.L. Oxidation of proteins in neonatal lungs. Pediatrics 1994, 93, 764–768. [Google Scholar] [CrossRef]
- Piersigilli, F.; Bhandari, V. Biomarkers in neonatology: The new "omics" of bronchopulmonary dysplasia. J Matern Fetal Neonatal Med. 2016, 29, 1758–1764. [Google Scholar] [CrossRef]
- Liu, C.Q.; Liu, X.Y.; Ouyang, P.W.; Liu, Q.; Huang, X.M.; Xiao, F.; Cui, Y.H.; Zhou, Q.; Pan, H.W. Ferrostatin-1 attenuates pathological angiogenesis in oxygen-induced retinopathy via inhibition of ferroptosis. Exp Eye Res. 2023, 226, 109347. [Google Scholar] [CrossRef]
- Faa, G.; Messana, I.; Coni, P.; Piras, M.; Pichiri, G.; Piludu, M.; Iavarone, F.; Desiderio, C.; Vento, G.; Tirone, C.; et al. Thymosin β4 and β10 Expression in Human Organs during Development: A Review. Cells 2024, 27, 1115. [Google Scholar] [CrossRef]
- Hannappel, E.; Huff, T. The thymosins. Prothymosin alpha, parathymosin, and beta-tymosins: Structure and function. Vitam Horm. 2003, 66, 257–296. [Google Scholar]
- Smart, N.; Rossdeutsch, A.; Riley, P.R. Thymosin beta4 and angiogenesis: Modes of action and therapeutic potential. Angiogenesis 2007, 10, 229–241. [Google Scholar] [CrossRef] [PubMed]
- Smart, N.; Rossdeutsch, A.; Riley, P.R. Thymosin beta4 and angiogenesis: Modes of action and therapeutic potential. Angiogenesis 2007, 10, 229–241. [Google Scholar] [CrossRef] [PubMed]
- Renga, G.; Oikonomou, V.; Stincardini, C.; Pariano, M.; Borghi, M.; Costantini, C.; Bartoli, A.; Garaci, E.; Goldstein, A.L.; Romani, L. Thymosin β4 limits inflammation through autophagy. Expert Opin Biol Ther. 2018, 18 (Suppl. 1), 171–175. [Google Scholar] [CrossRef]
- Evans, M.A.; Smart, N.; Dubé, K.N.; Bollini, S.; Clark, J.E.; Evans, H.G.; Taams, L.S.; Richardson, R.; Lévesque, M.; Martin, P.; et al. Thymosin β4-sulfoxide attenuates inflammatory cell infiltration and promotes cardiac wound healing. Nat Commun. 2013, 4, 2081. [Google Scholar] [CrossRef]
- Vasilopoulou, E.; Winyard, P.J.; Riley, P.R.; Long, D.A. The role of thymosin-β4 in kidney disease. Expert Opin Biol Ther. 2015, 15 (Suppl. 1), S187–S190. [Google Scholar] [CrossRef] [PubMed]
- Fanni, D.; Gerosa, C.; Nemolato, S.; Locci, A.; Marinelli, V.; Cabras, T.; Messana, I.; Fanos, V.; Castagnola, M.; Faa, G. Thymosin beta 10 expression in developing human salivary glands. Early Hum Dev. 2011, 87, 779–783. [Google Scholar] [CrossRef]
- Zhang, X.; Ren, D.; Guo, L.; Wang, L.; Wu, S.; Lin, C.; Ye, L.; Zhu, J.; Li, J.; Song, L.; et al. Thymosin beta 10 is a key regulator of tumorigenesis and metastasis and a novel serum marker in breast cancer. Breast Cancer Res. 2017, 19, 15. [Google Scholar] [CrossRef]
- Li, Z.; Li, Y.; Tian, Y.; Li, N.; Shen, L.; Zhao, Y. Pan-cancer analysis identifies the correlations of Thymosin Beta 10 with predicting prognosis and immunotherapy response. Front Immunol. 2023, 14, 1170539. [Google Scholar] [CrossRef]
- Castagnola, M.; Inzitari, R.; Fanali, C.; Iavarone, F.; Vitali, A.; Desiderio, C.; Vento, G.; Tirone, C.; Romagnoli, C.; Cabras, T.; et al. The surprising composition of the salivary proteome of preterm human newborn. Mol. Cell. Proteomics 2011, 10, M110.003467. [Google Scholar] [CrossRef]
- Inzitari, R.; Vento, G.; Capoluongo, E.; Boccacci, S.; Fanali, C.; Cabras, T.; Romagnoli, C.; Giardina, B.; Messana, I.; Castagnola, M. Proteomic analysis of salivary acidic proline-rich proteins in human preterm and at-term newborns. J Proteome Res. 2007, 6, 1371–1377. [Google Scholar] [CrossRef]
- Julious, S.A. Sample size of 12 per group rule of thumb for a pilot study. Pharmaceut. Statist. 2005, 4, 287–291. [Google Scholar] [CrossRef]
- Zhang, Z.; Marshall, G.A. A universal algorithm for fast and automated charge state deconvolution of electrospray mass-to-charge ratio spectra. J. Am. Soc. Mass Spectrom. 1998, 9, 225–233. [Google Scholar] [CrossRef]
- Levin, Y.; Schwarz, E.; Wang, L.; Leweke, F.M.; Bahn, S. Labelfree LC-MS/MS quantitative proteomics for large-scale biomarker discovery in complex samples. J. Sep. Sci. 2007, 30, 2198–2203. [Google Scholar] [CrossRef] [PubMed]
- Ong, S.E.; Mann, M. Mass spectrometry-based proteomics turns quantitative. Nat. Chem. Biol. 2005, 1, 252–262. [Google Scholar] [CrossRef] [PubMed]
- Messana, I.; Manconi, B.; Cabras, T.; Boroumand, M.; Sanna, M.T.; Iavarone, F.; Olianas, A.; Desiderio, C.; Rossetti, D.V.; Vincenzoni, F.; et al. The Post-Translational Modifications of Human Salivary Peptides and Proteins Evidenced by Top-Down Platforms. Int J Mol Sci. 2023, 24, 12776. [Google Scholar] [CrossRef]
- Nemolato, S.; Messana ICabras, T.; Manconi, B.; Inzitari, R.; Fanali, C.; Vento, G.; Tirone, C.; Romagnoli, C.; Riva, A.; Fanni, D.; et al. Thymosin beta(4) and beta(10) levels in pre-term newborn oral cavity and foetal salivary glands evidence a switch of secretion during foetal development. PLoS ONE 2009, 4, e5109. [Google Scholar] [CrossRef]
- Evans, M.A.; Smart, N.; Dubé, K.N.; Bollini, S.; Clark, J.E.; Evans, H.G.; Taams, L.S.; Richardson, R.; Lévesque, M.; Martin, P.; et al. Thymosin b4-sulfoxide attenuates inflammatory cell infiltration and promotes cardiac wound healing. Nature Communications 2013, 4, 2081. [Google Scholar] [CrossRef]
- Young, J.D.; Gracie, J.A.; Stevenson, R.D.; Lawrence, A.J.; Liew, F.Y.; McInnes, I.B. Thymosin beta4 sylphoxide: Potential role in resolution of inflammation? Arthritis Res. 2001, 3, A1–A47. [Google Scholar] [CrossRef]
- Faa, G.; Piras, M.; Mancuso, L.; Coni, P.; Pichiri, G.; Orrù, G.; Fanni, D.; Gerosa, C.; Cao, G.; Taibi, R.; et al. Thymosin beta-4 prenatal administration improves fetal development and halts side effects due to preterm delivery. Eur. Rev. Med. Pharmacol. Sci. 2021, 25, 431–437. [Google Scholar]
| Genaral characteristics | |
|---|---|
| Gestational age, weeks | 28.0 [25.7-29.6] |
| Neonatal weight, grams Male sex Vaginal delivery ROP 3-4 stage BPD moderate-severe |
940 [790-1180] 11/18 (61.1%) 6/18 (33.3%) 4/18 (22.2%) 5/18 (27.8%) |
| ROP stage 3-4 | Control group | p | |
|---|---|---|---|
| Tβ4 | 8.30*107 [4.20*107-2.60*108] | 1.40*108 [3.825*107-6.10*108] | 0.137 |
| Tβ10 | 2.70*107 [5.85*106-6.10*107] | 3.65*107 [7.20*106-1.55*108] | 0.265 |
| %ox Tβ4 | 7.87 [3.00-13.89] | 6.51 [2.91-16.60] | 0.870 |
| %ox Tβ10 | 4.37 [1.15-10.24] | 5.53 [2.12-11.69] | 0.296 |
| BPD Moderate-severe | Control group | p | |
|---|---|---|---|
| Tβ4 | 1.10*108 [4.75*107-3.75*108] | 1.45*108 [3.75*107-6.90*108] | 0.316 |
| Tβ10 | 3.10*107 [8.05*106-1.40*108] | 2.85*107 [7.10*106-1.28*108] | 0.832 |
| %ox Tβ4 | 5.88 [3.08-11.4] | 8.46 [2.81-17.79] | 0.416 |
| %ox Tβ10 | 4.32 [1.35-9.13] | 7.16 [2.64-15.86] | 0.024 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).